HRP20100603T1 - Derivati pirimidina koji se koriste kao inhibitori pi-3 kinaze - Google Patents
Derivati pirimidina koji se koriste kao inhibitori pi-3 kinaze Download PDFInfo
- Publication number
- HRP20100603T1 HRP20100603T1 HR20100603T HRP20100603T HRP20100603T1 HR P20100603 T1 HRP20100603 T1 HR P20100603T1 HR 20100603 T HR20100603 T HR 20100603T HR P20100603 T HRP20100603 T HR P20100603T HR P20100603 T1 HRP20100603 T1 HR P20100603T1
- Authority
- HR
- Croatia
- Prior art keywords
- substituted
- unsubstituted
- group
- compound according
- hydrogen
- Prior art date
Links
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 49
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 36
- 239000001257 hydrogen Substances 0.000 claims abstract 36
- 229910052736 halogen Inorganic materials 0.000 claims abstract 25
- 150000002367 halogens Chemical class 0.000 claims abstract 25
- 125000000217 alkyl group Chemical group 0.000 claims abstract 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 21
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 15
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 14
- 125000003118 aryl group Chemical group 0.000 claims abstract 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 13
- 150000002431 hydrogen Chemical class 0.000 claims abstract 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 13
- 150000003839 salts Chemical class 0.000 claims abstract 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 9
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 7
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 7
- -1 hydroxy, amino Chemical group 0.000 claims abstract 6
- 229940124530 sulfonamide Drugs 0.000 claims abstract 4
- 150000003456 sulfonamides Chemical class 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical group C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 2
- 229950000578 vatalanib Drugs 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- XKVODZRJCXLQCY-CYBMUJFWSA-N 1-[(3r)-3-[6-(2,4-diaminopyrimidin-5-yl)-2-morpholin-4-ylpyrimidin-4-yl]oxypiperidin-1-yl]ethanone Chemical compound C1N(C(=O)C)CCC[C@H]1OC1=CC(C=2C(=NC(N)=NC=2)N)=NC(N2CCOCC2)=N1 XKVODZRJCXLQCY-CYBMUJFWSA-N 0.000 claims 1
- WJKGLEPYSVEMMR-CYBMUJFWSA-N 1-[(3r)-3-[6-[6-amino-4-(trifluoromethyl)pyridin-3-yl]-2-morpholin-4-ylpyrimidin-4-yl]oxypyrrolidin-1-yl]ethanone Chemical compound C1N(C(=O)C)CC[C@H]1OC1=CC(C=2C(=CC(N)=NC=2)C(F)(F)F)=NC(N2CCOCC2)=N1 WJKGLEPYSVEMMR-CYBMUJFWSA-N 0.000 claims 1
- WJKGLEPYSVEMMR-ZDUSSCGKSA-N 1-[(3s)-3-[6-[6-amino-4-(trifluoromethyl)pyridin-3-yl]-2-morpholin-4-ylpyrimidin-4-yl]oxypyrrolidin-1-yl]ethanone Chemical compound C1N(C(=O)C)CC[C@@H]1OC1=CC(C=2C(=CC(N)=NC=2)C(F)(F)F)=NC(N2CCOCC2)=N1 WJKGLEPYSVEMMR-ZDUSSCGKSA-N 0.000 claims 1
- IRGQATMSWNBAAN-UHFFFAOYSA-N 1-[2-[6-amino-4-(trifluoromethyl)pyridin-3-yl]-6-morpholin-4-ylpyrimidin-4-yl]piperidin-2-one Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CCOCC2)=CC(N2C(CCCC2)=O)=N1 IRGQATMSWNBAAN-UHFFFAOYSA-N 0.000 claims 1
- DAVMGHKVRIVQHK-UHFFFAOYSA-N 1-[6-[6-amino-4-(trifluoromethyl)pyridin-3-yl]-2-morpholin-4-ylpyrimidin-4-yl]-3-phenylimidazolidin-2-one Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2C(N(CC2)C=2C=CC=CC=2)=O)=NC(N2CCOCC2)=N1 DAVMGHKVRIVQHK-UHFFFAOYSA-N 0.000 claims 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims 1
- HLWTXVAXGWFIGD-UHFFFAOYSA-N 2-amino-5-[2-morpholin-4-yl-6-(quinolin-3-ylamino)pyrimidin-4-yl]pyridine-4-carbonitrile Chemical compound C1=NC(N)=CC(C#N)=C1C1=CC(NC=2C=C3C=CC=CC3=NC=2)=NC(N2CCOCC2)=N1 HLWTXVAXGWFIGD-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- GPSNQTAHWLFUMS-UHFFFAOYSA-N 5-(2-morpholin-4-yl-6-piperidin-4-yloxypyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(OC2CCNCC2)=NC(N2CCOCC2)=N1 GPSNQTAHWLFUMS-UHFFFAOYSA-N 0.000 claims 1
- QJJOWBBWAJMFKV-UHFFFAOYSA-N 5-(2-morpholin-4-yl-6-piperidin-4-yloxypyrimidin-4-yl)pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1C1=CC(OC2CCNCC2)=NC(N2CCOCC2)=N1 QJJOWBBWAJMFKV-UHFFFAOYSA-N 0.000 claims 1
- ZCLGMFVGVKWRBN-UHFFFAOYSA-N 5-(2-morpholin-4-yl-6-pyridin-3-yloxypyrimidin-4-yl)pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=CC(OC=2C=NC=CC=2)=NC(N2CCOCC2)=N1 ZCLGMFVGVKWRBN-UHFFFAOYSA-N 0.000 claims 1
- BVDFIHKEDFXZGJ-UHFFFAOYSA-N 5-[2-morpholin-4-yl-6-(2-phenylmorpholin-4-yl)pyrimidin-4-yl]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=CC(N2CC(OCC2)C=2C=CC=CC=2)=NC(N2CCOCC2)=N1 BVDFIHKEDFXZGJ-UHFFFAOYSA-N 0.000 claims 1
- CXHHDYIDOQJRSB-UHFFFAOYSA-N 5-[2-morpholin-4-yl-6-(oxan-4-yloxy)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(OC2CCOCC2)=NC(N2CCOCC2)=N1 CXHHDYIDOQJRSB-UHFFFAOYSA-N 0.000 claims 1
- USBKPGIHJDOWOB-LLVKDONJSA-N 5-[2-morpholin-4-yl-6-[(3r)-oxolan-3-yl]oxypyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(O[C@H]2COCC2)=NC(N2CCOCC2)=N1 USBKPGIHJDOWOB-LLVKDONJSA-N 0.000 claims 1
- SSUDJOSHFSFMEP-GFCCVEGCSA-N 5-[2-morpholin-4-yl-6-[(3r)-piperidin-3-yl]oxypyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(O[C@H]2CNCCC2)=NC(N2CCOCC2)=N1 SSUDJOSHFSFMEP-GFCCVEGCSA-N 0.000 claims 1
- USBKPGIHJDOWOB-NSHDSACASA-N 5-[2-morpholin-4-yl-6-[(3s)-oxolan-3-yl]oxypyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(O[C@@H]2COCC2)=NC(N2CCOCC2)=N1 USBKPGIHJDOWOB-NSHDSACASA-N 0.000 claims 1
- SSUDJOSHFSFMEP-LBPRGKRZSA-N 5-[2-morpholin-4-yl-6-[(3s)-piperidin-3-yl]oxypyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(O[C@@H]2CNCCC2)=NC(N2CCOCC2)=N1 SSUDJOSHFSFMEP-LBPRGKRZSA-N 0.000 claims 1
- VNVTYBPKOXYXRR-UHFFFAOYSA-N 6-(2-aminopyrimidin-5-yl)-n-(2-methoxyethyl)-2-morpholin-4-ylpyrimidin-4-amine Chemical compound N=1C(NCCOC)=CC(C=2C=NC(N)=NC=2)=NC=1N1CCOCC1 VNVTYBPKOXYXRR-UHFFFAOYSA-N 0.000 claims 1
- WZUWBEVLBFHSDB-UHFFFAOYSA-N 6-(2-aminopyrimidin-5-yl)-n-methyl-2-morpholin-4-yl-n-(oxan-4-yl)pyrimidin-4-amine Chemical compound C=1C(C=2C=NC(N)=NC=2)=NC(N2CCOCC2)=NC=1N(C)C1CCOCC1 WZUWBEVLBFHSDB-UHFFFAOYSA-N 0.000 claims 1
- DWXBYTYWBANFCB-UHFFFAOYSA-N 6-(2-aminopyrimidin-5-yl)-n-tert-butyl-2-morpholin-4-ylpyrimidin-4-amine Chemical compound N=1C(NC(C)(C)C)=CC(C=2C=NC(N)=NC=2)=NC=1N1CCOCC1 DWXBYTYWBANFCB-UHFFFAOYSA-N 0.000 claims 1
- VROANLXOBIMUFA-UHFFFAOYSA-N 6-(6-aminopyridin-3-yl)-n-(6-methoxypyridin-3-yl)-2-morpholin-4-ylpyrimidin-4-amine Chemical compound C1=NC(OC)=CC=C1NC1=CC(C=2C=NC(N)=CC=2)=NC(N2CCOCC2)=N1 VROANLXOBIMUFA-UHFFFAOYSA-N 0.000 claims 1
- ONFWLFUSCUBPIH-UHFFFAOYSA-N 6-[6-amino-4-(trifluoromethyl)pyridin-3-yl]-2-morpholin-4-yl-n-[4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]pyrimidin-4-amine Chemical compound C1CN(C(C)C)CCC1OC(C=C1)=CC=C1NC1=CC(C=2C(=CC(N)=NC=2)C(F)(F)F)=NC(N2CCOCC2)=N1 ONFWLFUSCUBPIH-UHFFFAOYSA-N 0.000 claims 1
- QFLIOAOFLZFXMC-UHFFFAOYSA-N 6-[6-amino-4-(trifluoromethyl)pyridin-3-yl]-2-morpholin-4-yl-n-[6-(1-propan-2-ylpiperidin-4-yl)oxypyridin-3-yl]pyrimidin-4-amine Chemical compound C1CN(C(C)C)CCC1OC(N=C1)=CC=C1NC1=CC(C=2C(=CC(N)=NC=2)C(F)(F)F)=NC(N2CCOCC2)=N1 QFLIOAOFLZFXMC-UHFFFAOYSA-N 0.000 claims 1
- JRTWKORVIFDHNA-UHFFFAOYSA-N 6-[6-amino-4-(trifluoromethyl)pyridin-3-yl]-n-[3-methoxy-4-(1-propan-2-ylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylpyrimidin-4-amine Chemical compound C=1C=C(OC2CCN(CC2)C(C)C)C(OC)=CC=1NC(N=1)=CC(C=2C(=CC(N)=NC=2)C(F)(F)F)=NC=1N1CCOCC1 JRTWKORVIFDHNA-UHFFFAOYSA-N 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- OLEQMKFFMNHBSI-UHFFFAOYSA-N methyl 4-[6-(2-amino-6-oxo-1h-pyrimidin-5-yl)-2-morpholin-4-ylpyrimidin-4-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCC1OC1=CC(C=2C(NC(N)=NC=2)=O)=NC(N2CCOCC2)=N1 OLEQMKFFMNHBSI-UHFFFAOYSA-N 0.000 claims 1
- GJOPPYUMRDERJE-UHFFFAOYSA-N n-[3-[6-(6-aminopyridin-3-yl)-2-morpholin-4-ylpyrimidin-4-yl]pyridin-2-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=NC=CC=C1C1=CC(C=2C=NC(N)=CC=2)=NC(N2CCOCC2)=N1 GJOPPYUMRDERJE-UHFFFAOYSA-N 0.000 claims 1
- SYPNVSVTWDNXJU-UHFFFAOYSA-N n-[6-(2-aminopyrimidin-5-yl)-2-morpholin-4-ylpyrimidin-4-yl]-5-methoxyquinolin-3-amine Chemical compound C1=C2C(OC)=CC=CC2=NC=C1NC(N=1)=CC(C=2C=NC(N)=NC=2)=NC=1N1CCOCC1 SYPNVSVTWDNXJU-UHFFFAOYSA-N 0.000 claims 1
- LICCCQJZOPRJSR-UHFFFAOYSA-N n-[6-(2-aminopyrimidin-5-yl)-2-morpholin-4-ylpyrimidin-4-yl]quinolin-3-amine Chemical compound C1=NC(N)=NC=C1C1=CC(NC=2C=C3C=CC=CC3=NC=2)=NC(N2CCOCC2)=N1 LICCCQJZOPRJSR-UHFFFAOYSA-N 0.000 claims 1
- AAGMAOVYPSOAOX-UHFFFAOYSA-N n-[6-(6-amino-4-fluoropyridin-3-yl)-2-morpholin-4-ylpyrimidin-4-yl]quinolin-3-amine Chemical compound C1=NC(N)=CC(F)=C1C1=CC(NC=2C=C3C=CC=CC3=NC=2)=NC(N2CCOCC2)=N1 AAGMAOVYPSOAOX-UHFFFAOYSA-N 0.000 claims 1
- NHIATJMNLHUPCB-UHFFFAOYSA-N n-[6-[6-amino-4-(trifluoromethyl)pyridin-3-yl]-2-morpholin-4-ylpyrimidin-4-yl]-4-[2-(diethylamino)ethyl]-1,3-thiazol-2-amine Chemical compound CCN(CC)CCC1=CSC(NC=2N=C(N=C(C=2)C=2C(=CC(N)=NC=2)C(F)(F)F)N2CCOCC2)=N1 NHIATJMNLHUPCB-UHFFFAOYSA-N 0.000 claims 1
- HRKLHXAWCDUDFO-UHFFFAOYSA-N n-[6-[6-amino-4-(trifluoromethyl)pyridin-3-yl]-2-morpholin-4-ylpyrimidin-4-yl]-4-phenyl-1,3-thiazol-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(NC=2SC=C(N=2)C=2C=CC=CC=2)=NC(N2CCOCC2)=N1 HRKLHXAWCDUDFO-UHFFFAOYSA-N 0.000 claims 1
- PLVUFUDHSFMSTP-UHFFFAOYSA-N n-[6-[6-amino-4-(trifluoromethyl)pyridin-3-yl]-2-morpholin-4-ylpyrimidin-4-yl]-5-(diethylaminomethyl)-1,3-thiazol-2-amine Chemical compound S1C(CN(CC)CC)=CN=C1NC1=CC(C=2C(=CC(N)=NC=2)C(F)(F)F)=NC(N2CCOCC2)=N1 PLVUFUDHSFMSTP-UHFFFAOYSA-N 0.000 claims 1
- MFWHRPHYUREIFE-UHFFFAOYSA-N n-[6-[6-amino-4-(trifluoromethyl)pyridin-3-yl]-5-methyl-2-morpholin-4-ylpyrimidin-4-yl]-4-phenyl-1,3-thiazol-2-amine Chemical compound N1=C(N2CCOCC2)N=C(C=2C(=CC(N)=NC=2)C(F)(F)F)C(C)=C1NC(SC=1)=NC=1C1=CC=CC=C1 MFWHRPHYUREIFE-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 150000003527 tetrahydropyrans Chemical class 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76078906P | 2006-01-20 | 2006-01-20 | |
PCT/US2007/001708 WO2007084786A1 (fr) | 2006-01-20 | 2007-01-22 | Derives de pyrimidine utilises en tant qu’inhibiteurs de kinase pi-3 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100603T1 true HRP20100603T1 (hr) | 2010-12-31 |
Family
ID=37951939
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100603T HRP20100603T1 (hr) | 2006-01-20 | 2010-11-09 | Derivati pirimidina koji se koriste kao inhibitori pi-3 kinaze |
HRP20130796TT HRP20130796T1 (en) | 2006-01-20 | 2013-08-22 | Pyrimidine derivatives used as pi-3 kinase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130796TT HRP20130796T1 (en) | 2006-01-20 | 2013-08-22 | Pyrimidine derivatives used as pi-3 kinase inhibitors |
Country Status (41)
Country | Link |
---|---|
US (2) | US8217035B2 (fr) |
EP (2) | EP2261223B1 (fr) |
JP (1) | JP5161110B2 (fr) |
KR (1) | KR101353829B1 (fr) |
CN (1) | CN101389622B (fr) |
AR (2) | AR059087A1 (fr) |
AT (1) | ATE478064T1 (fr) |
AU (1) | AU2007206048B2 (fr) |
BR (1) | BRPI0707189B1 (fr) |
CA (1) | CA2636993C (fr) |
CR (1) | CR10163A (fr) |
CY (1) | CY1111091T1 (fr) |
DE (1) | DE602007008529D1 (fr) |
DK (2) | DK2261223T3 (fr) |
EA (1) | EA018083B1 (fr) |
EC (1) | ECSP088630A (fr) |
ES (2) | ES2427624T3 (fr) |
GE (1) | GEP20115147B (fr) |
GT (1) | GT200800143A (fr) |
HK (1) | HK1122031A1 (fr) |
HN (1) | HN2008001144A (fr) |
HR (2) | HRP20100603T1 (fr) |
IL (1) | IL192763A (fr) |
JO (1) | JO2660B1 (fr) |
MA (1) | MA30208B1 (fr) |
ME (2) | MEP3908A (fr) |
MY (1) | MY144233A (fr) |
NO (1) | NO342183B1 (fr) |
NZ (1) | NZ569771A (fr) |
PE (1) | PE20071322A1 (fr) |
PL (2) | PL1984350T3 (fr) |
PT (2) | PT1984350E (fr) |
RS (2) | RS52928B (fr) |
SI (2) | SI2261223T1 (fr) |
SM (1) | SMP200800048B (fr) |
SV (1) | SV2008002984A (fr) |
TN (1) | TNSN08305A1 (fr) |
TW (2) | TWI385170B (fr) |
UA (1) | UA96284C2 (fr) |
WO (1) | WO2007084786A1 (fr) |
ZA (1) | ZA200806017B (fr) |
Families Citing this family (328)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
CA2660758A1 (fr) | 2006-08-24 | 2008-02-27 | Astrazeneca Ab | Derives de la morpholino pyrimidine utiles dans le traitement de maladies proliferatives |
MY180595A (en) | 2006-12-07 | 2020-12-03 | Genentech Inc | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
WO2008098058A1 (fr) * | 2007-02-06 | 2008-08-14 | Novartis Ag | Inhibiteurs de la pi3-kinase et procédés de leur utilisation |
JP5676249B2 (ja) * | 2007-04-20 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 |
EP2155689B1 (fr) | 2007-05-31 | 2015-07-08 | Boehringer Ingelheim International GmbH | Antagonistes du récepteur ccr2 et leurs utilisations |
KR20100042280A (ko) | 2007-07-09 | 2010-04-23 | 아스트라제네카 아베 | Mtor 키나제 및/또는 pi3k와 연관된 질환에 사용되는 모르폴리노 피리미딘 유도체 |
WO2009017838A2 (fr) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinaisons d'inhibiteurs jak-2 et d'autres agents |
WO2009055418A1 (fr) * | 2007-10-22 | 2009-04-30 | Smithkline Beecham Corporation | Dérivés de pyridosulfonamide en tant qu'inhibiteurs de pi3 kinase |
WO2009066084A1 (fr) * | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2-morpholinopyrimidines et leur utilisation en tant qu'inhibiteurs de kinase pi3 |
WO2009093981A1 (fr) * | 2008-01-23 | 2009-07-30 | S Bio Pte Ltd | Composés de triazine comme inhibiteurs de la kinase |
AU2009221164B2 (en) * | 2008-03-05 | 2012-07-26 | Novartis Ag | Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
MX338088B (es) * | 2008-03-26 | 2016-04-01 | Novartis Ag | Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf). |
AU2012203914C1 (en) * | 2008-03-26 | 2013-11-28 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of VEGF-driven angiogenic processes |
JP2011515462A (ja) * | 2008-03-27 | 2011-05-19 | アウククランド ウニセルビセス リミテッド | 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
KR101860057B1 (ko) | 2008-05-21 | 2018-05-21 | 어리어드 파마슈티칼스, 인코포레이티드 | 키나아제 억제제로서 포스포러스 유도체 |
US20110105500A1 (en) * | 2008-06-27 | 2011-05-05 | S*Bio Pte Ltd. | Pyrazine substituted purines |
CN102089007B (zh) * | 2008-07-11 | 2013-05-15 | 诺瓦提斯公司 | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 |
CA2731909A1 (fr) * | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | 5-alcynyl-pyrimidines |
US20100068204A1 (en) * | 2008-09-12 | 2010-03-18 | Wyeth | 4-aryloxyquinolin-2(1h)-ones as mtor kinase and pi3 kinase inhibitors, for use as anti-cancer agents |
CN102170873B (zh) * | 2008-10-01 | 2014-07-30 | 诺华股份有限公司 | 用于治疗与hedgehog通路有关的病症的smoothened拮抗 |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
JP2012506898A (ja) * | 2008-10-31 | 2012-03-22 | ノバルティス アーゲー | ホスファチジルイノシトール−3−キナーゼ(PI3K)阻害剤とmTOR阻害剤との併用剤 |
WO2010059788A1 (fr) * | 2008-11-20 | 2010-05-27 | Genentech, Inc. | Composés inhibiteurs de pi3k de type pyrazolopyridine et leurs procédés d'utilisation |
EA020548B1 (ru) | 2008-12-19 | 2014-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл |
EP2404918B1 (fr) | 2009-03-05 | 2016-11-30 | Daiichi Sankyo Company, Limited | Dérivé de pyridine en tant qu' inhibiteur de ppary |
EP2411387B1 (fr) | 2009-03-27 | 2015-08-19 | VetDC, Inc. | Pyrimidinyl et 1,3,5-triazinyl benzimidazole sulfonamides et leur utilisation en thérapie anticancéreuse |
US20120046333A1 (en) * | 2009-04-09 | 2012-02-23 | Oncothyreon Incorporated | Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
CN102958518A (zh) * | 2009-05-15 | 2013-03-06 | 诺瓦提斯公司 | 磷脂酰肌醇3-激酶抑制剂和抗糖尿病化合物的组合 |
AU2010254161A1 (en) * | 2009-05-27 | 2011-11-10 | F. Hoffmann-La Roche Ag | Bicyclic pyrimidine PI3K inhibitor compounds selective for p110 delta, and methods of use |
AR080945A1 (es) | 2009-07-07 | 2012-05-23 | Pathway Therapeutics Inc | Pirimidinil y 1,3,5-triazinil benzimidazoles y su uso en la terapia contra el cancer |
US20120065166A1 (en) * | 2009-08-12 | 2012-03-15 | Virginia Espina | Bone Modulators And Methods Therewith |
CN101993416B (zh) * | 2009-08-27 | 2013-09-11 | 中国科学院上海药物研究所 | 喹啉类化合物、其制备方法、包含该化合物的药物组合物及该化合物的用途 |
KR20120063515A (ko) * | 2009-09-09 | 2012-06-15 | 아빌라 테라퓨틱스, 인크. | Pi3 키나제 억제제 및 이들의 용도 |
CA2777741A1 (fr) * | 2009-10-16 | 2011-04-21 | Rib-X Pharmaceuticals, Inc. | Composes antimicrobiens et methodes de realisation et d'utilisation de ceux-ci |
DK2488532T3 (en) | 2009-10-16 | 2018-08-13 | Melinta Therapeutics Inc | ANTIMICROBIAL COMPOUNDS AND PROCEDURES FOR PREPARING AND USING THE SAME |
ES2524829T3 (es) | 2009-12-17 | 2014-12-12 | Boehringer Ingelheim International Gmbh | Nuevos antagonistas del receptor CCR2 y usos de los mismos |
GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
US8946218B2 (en) | 2010-05-12 | 2015-02-03 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments |
EP2569298B1 (fr) | 2010-05-12 | 2015-11-25 | Boehringer Ingelheim International GmbH | Nouveaux antagonistes du récepteur ccr2, son procédé de production et utilisation associée en tant que médicaments |
JP5647339B2 (ja) | 2010-05-17 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr2アンタゴニスト及びこれらの使用 |
US9018212B2 (en) | 2010-05-25 | 2015-04-28 | Boehringer Ingelheim International Gmbh | Pyridazine carboxamides as CCR2 receptor antagonists |
EP2576538B1 (fr) | 2010-06-01 | 2015-10-28 | Boehringer Ingelheim International GmbH | Nouveaux antagonistes de CCR2 |
SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
CN103209955A (zh) | 2010-09-07 | 2013-07-17 | 第一三共株式会社 | 制备安息香酸酯的方法 |
DK3040333T3 (da) * | 2010-10-01 | 2019-01-02 | Novartis Ag | Krystallinske former af 5-(2,6-di-4-morpholinyl-4-pyridmidinyl)-4-trifluormethylpyridin-2-amin, en pik3-hæmmer |
AU2011315831B2 (en) * | 2010-10-14 | 2015-01-22 | Takeda Pharmaceutical Company Limited | Methods for inhibiting cell proliferation in EGFR-driven cancers |
US20130310352A1 (en) | 2010-11-12 | 2013-11-21 | Board Of Regents, The University Of Texas System | Dexamethasone combination therapy |
BR112013011533A2 (pt) * | 2010-11-12 | 2016-08-09 | Bayer Ip Gmbh | processo para a preparação de 2, 2 - difluoroetilamina a partir de prop-2-en-1-amina |
CA2822565A1 (fr) | 2010-12-21 | 2012-06-28 | Novartis Ag | Composes bi-heteroaryles en tant qu'inhibiteurs de vps34 |
EP2673268A1 (fr) * | 2011-02-11 | 2013-12-18 | Dana-Farber Cancer Institute, Inc. | Procédé d'inhibition de cellules tumorales d'hamartome |
CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
KR101940831B1 (ko) | 2011-03-28 | 2019-01-21 | 메이 파마, 아이엔씨. | (알파-치환된 아르알킬아미노 및 헤테로아릴알킬아미노)피리미딘일 및 1,3,5-트라이아진일 벤즈이미다졸, 이들을 함유하는 약학 조성물, 및 증식성 질병의 치료에 사용하기 위한 이들 화합물 |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
AU2012279117A1 (en) | 2011-07-01 | 2014-01-09 | Novartis Ag | Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer |
WO2013010839A1 (fr) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Antagonistes de ccr2 nouveaux et sélectifs |
JP6105578B2 (ja) | 2011-07-21 | 2017-03-29 | トレロ ファーマシューティカルズ, インコーポレイテッド | 複素環式プロテインキナーゼ阻害剤 |
EP2750675A1 (fr) | 2011-08-31 | 2014-07-09 | Novartis AG | Combinaisons synergiques d'inhibiteurs de pi3k et de mek |
BR112014004577A2 (pt) | 2011-09-01 | 2017-04-04 | Novartis Ag | inibidor pi3k para uso no tratamento de câncer ósseo ou para prevenção por metástase de células cancerosas primárias para os ossos |
CA2849995A1 (fr) | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante |
WO2013049581A1 (fr) * | 2011-09-30 | 2013-04-04 | Beth Israel Deaconess Medical Center Inc. | Compositions et méthodes de traitement de maladies de prolifération |
WO2013063000A1 (fr) * | 2011-10-28 | 2013-05-02 | Novartis Ag | Procédé de traitement de tumeurs stromales gastro-intestinales |
AU2012338869A1 (en) * | 2011-11-15 | 2014-06-05 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the Janus Kinase 2-Signal Transducer and Activator of Transcription 5 pathway |
UY34632A (es) * | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
RS58043B1 (sr) | 2012-04-24 | 2019-02-28 | Vertex Pharma | Inhibitori dna-pk |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
CA2872526A1 (fr) | 2012-05-16 | 2013-11-21 | Novartis Ag | Regime posologique pour un inhibiteur de pi-3 kinase |
KR20160027218A (ko) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
EP2858631A1 (fr) * | 2012-06-06 | 2015-04-15 | Novartis AG | Combinaison d'un inhibiteur de 17-alpha-hydroxylase (c17,20-lyase) et d'un inhibiteur spécifique de pi-3k pour le traitement d'une maladie tumorale |
WO2013192367A1 (fr) | 2012-06-22 | 2013-12-27 | Novartis Ag | Traitement d'une tumeur neuroendocrine |
US20150224190A1 (en) | 2012-07-06 | 2015-08-13 | Mohamed Bentires-Alj | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction |
IN2015DN01408A (fr) | 2012-07-23 | 2015-07-03 | Sphaera Pharma Pte Ltd | |
US20150216870A1 (en) * | 2012-08-16 | 2015-08-06 | Novartis Ag | Combination of PI3K Inhibitor and C-Met Inhibitor |
CN102952086B (zh) * | 2012-09-28 | 2013-08-28 | 天津科创医药中间体技术生产力促进有限公司 | 一种2-吗啉基取代嘧啶类化合物的制备方法 |
EP2909181B1 (fr) | 2012-10-16 | 2017-08-09 | Tolero Pharmaceuticals, Inc. | Modulateurs de pkm2 et procédés pour les utiliser |
AU2013336807B2 (en) * | 2012-10-23 | 2016-10-27 | Novartis Ag | Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
RU2661896C2 (ru) | 2012-11-16 | 2018-07-23 | Мерк Шарп И Доум Корп. | Пуриновые ингибиторы фосфатидилинозитол-3-киназы дельта человека |
WO2014093230A2 (fr) * | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions et procédés de fabrication de composés pyrimidine et pyridine ayant une activité inhibitrice de btk |
EP3251673A1 (fr) | 2012-12-13 | 2017-12-06 | IP Gesellschaft für Management mbH | Polythérapie comportant un inhibiteur de cdk4/6 et un inhibiteur de pi3k à utiliser dans le traitement du cancer |
CN104245693B (zh) * | 2012-12-14 | 2016-08-24 | 上海恒瑞医药有限公司 | 嘧啶类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
CN105358576B (zh) | 2013-02-20 | 2020-05-05 | 诺华股份有限公司 | 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症 |
GB201303109D0 (en) * | 2013-02-21 | 2013-04-10 | Domainex Ltd | Novel pyrimidine compounds |
CN105073099B (zh) * | 2013-03-06 | 2018-10-26 | 诺华股份有限公司 | 有机化合物的制剂 |
EP3527563B1 (fr) | 2013-03-12 | 2021-09-01 | Vertex Pharmaceuticals Incorporated | Inhibiteurs d'adn-pk |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
KR20150131224A (ko) | 2013-03-14 | 2015-11-24 | 노파르티스 아게 | 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
EP2970205B1 (fr) | 2013-03-14 | 2019-05-08 | Tolero Pharmaceuticals, Inc. | Inhibiteurs de jak2 et alk2 et leurs procédés d'utilisation |
MX366978B (es) | 2013-03-15 | 2019-08-01 | Novartis Ag | Conjugados de anticuerpo - farmaco. |
SI2976106T1 (sl) | 2013-03-21 | 2021-08-31 | Array Biopharma Inc. | Kombinacijska terapija, ki vsebuje zaviralec B-Raf in drugi zaviralec |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
JP6523251B2 (ja) * | 2013-05-01 | 2019-05-29 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | C−結合ヘテロシクロアルキル置換ピリミジン類及びそれらの用途 |
AU2014261894C1 (en) | 2013-05-01 | 2019-07-11 | F. Hoffmann-La Roche Ag | Biheteroaryl compounds and uses thereof |
PL2994126T3 (pl) | 2013-05-07 | 2018-11-30 | Novartis Ag | Kombinacja inhibitora kinazy pi3 z paklitakselem do stosowania w leczeniu lub zapobieganiu nowotworowi złośliwemu głowy i szyi |
AU2014279721A1 (en) | 2013-06-11 | 2015-12-03 | Novartis Ag | Pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent |
CN105338980A (zh) | 2013-06-18 | 2016-02-17 | 诺华股份有限公司 | 药物组合 |
EP3030237A1 (fr) | 2013-08-08 | 2016-06-15 | Novartis AG | Combinaisons d'inhibiteurs de pim kinase |
DK3033086T3 (da) | 2013-08-14 | 2022-01-03 | Novartis Ag | Kombinationsterapi til behandling af cancer |
WO2015022657A1 (fr) | 2013-08-16 | 2015-02-19 | Novartis Ag | Combinaisons pharmaceutiques |
CA2923179A1 (fr) | 2013-09-09 | 2015-03-12 | Melinta Therapeutics, Inc. | Composes antimicrobiens et procedes de fabrication et methodes d'utilisation de ceux-ci |
KR20160070066A (ko) | 2013-09-09 | 2016-06-17 | 멜린타 테라퓨틱스, 인크. | 항균 화합물, 및 이의 제조 방법 및 이용 방법 |
CN103483345B (zh) * | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
WO2015048312A1 (fr) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Méthodes de traitement de cancers hématologiques |
SG11201602962PA (en) | 2013-10-17 | 2016-05-30 | Vertex Pharma | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
EP3094340A1 (fr) * | 2014-01-15 | 2016-11-23 | Novartis AG | Combinaisons pharmaceutiques |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
WO2015131080A1 (fr) | 2014-02-28 | 2015-09-03 | Nimbus Lakshmi, Inc. | Inhibiteurs de tyk2 et leurs utilisations |
US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
CN106458968B (zh) | 2014-04-22 | 2019-06-25 | 巴塞尔大学 | 三嗪、嘧啶和吡啶衍生物的新制备方法 |
WO2016001789A1 (fr) * | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer |
WO2016001341A1 (fr) * | 2014-07-03 | 2016-01-07 | F. Hoffmann-La Roche Ag | Composés sulfonylaminopyridine, compositions et procédés d'utilisation associés |
US10786578B2 (en) | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
CN106659790A (zh) | 2014-08-12 | 2017-05-10 | 诺华股份有限公司 | 抗cdh6抗体药物缀合物 |
US11311512B2 (en) | 2014-08-12 | 2022-04-26 | Monash University | Lymph directing prodrugs |
CN105330699B (zh) * | 2014-08-13 | 2018-12-04 | 山东汇睿迪生物技术有限公司 | 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用 |
CN104151256B (zh) * | 2014-08-14 | 2016-08-24 | 西安交通大学 | 二取代苯甲酰胺类化合物及其合成方法和应用 |
RU2718914C2 (ru) | 2014-09-13 | 2020-04-15 | Новартис Аг | Сочетанные способы лечения с использованием ингибиторов alk |
CN105461714B (zh) * | 2014-09-29 | 2017-11-28 | 山东轩竹医药科技有限公司 | 并环类pi3k抑制剂 |
ES2774448T3 (es) | 2014-10-03 | 2020-07-21 | Novartis Ag | Terapias de combinación |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CR20170143A (es) | 2014-10-14 | 2017-06-19 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
JP6831783B2 (ja) | 2014-11-14 | 2021-02-17 | ノバルティス アーゲー | 抗体薬物コンジュゲート |
CN105085476B (zh) * | 2014-11-24 | 2018-03-09 | 苏州晶云药物科技有限公司 | 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺二盐酸盐的晶型及其制备方法 |
WO2016092508A1 (fr) | 2014-12-12 | 2016-06-16 | Massachusetts General Hospital | Traitement de métastases cérébrales du cancer du sein |
JP6397577B2 (ja) * | 2014-12-17 | 2018-09-26 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドShanghai Haiyan Pharmaceutical Technology Co., Ltd. | 2−モルホリノ−4,6−二置換ピリミジン誘導体、その製法および医薬における使用 |
WO2016100882A1 (fr) | 2014-12-19 | 2016-06-23 | Novartis Ag | Polythérapies |
MY186837A (en) | 2014-12-23 | 2021-08-25 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
CN105832741A (zh) * | 2015-01-16 | 2016-08-10 | 复旦大学 | Pi3k抑制剂与紫杉醇的药物组合物及其在制备抗肿瘤药物中的应用 |
BR112017018198A2 (pt) | 2015-02-27 | 2018-04-10 | Curtana Pharmaceuticals Inc | inibição da atividade de olig2 |
US20160251376A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
SG11201706756VA (en) | 2015-03-10 | 2017-09-28 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
MX2017011616A (es) | 2015-03-11 | 2018-04-11 | Melinta Therapeutics Inc | Compuestos antimicrobianos y métodos para hacerlos y usarlos. |
US9481665B2 (en) * | 2015-03-13 | 2016-11-01 | Yong Xu | Process for preparing PI3K inhibitor buparsilib |
EP3273959A1 (fr) * | 2015-03-25 | 2018-01-31 | Novartis Ag | Combinaisons pharmaceutiques |
WO2016151499A1 (fr) | 2015-03-25 | 2016-09-29 | Novartis Ag | Dérivés n-hétérocycliques formylés utilisés en tant qu'inhibiteurs de fgfr4 |
EP3310813A1 (fr) | 2015-06-17 | 2018-04-25 | Novartis AG | Conjugués anticorps-médicament |
WO2017004134A1 (fr) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Inhibiteurs d'irak et leurs utilisations |
JP6917910B2 (ja) | 2015-07-02 | 2021-08-11 | セントレクシオン セラピューティクス コーポレイション | (4−((3r,4r)−3−メトキシテトラヒドロ−ピラン−4−イルアミノ)ピペリジン−1−イル)(5−メチル−6−(((2r,6s)−6−(p−トリル)テトラヒドロ−2h−ピラン−2−イル)メチルアミノ)ピリミジン−4イル)メタノンクエン酸塩 |
WO2017009751A1 (fr) * | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Dérivés de pyrimidine |
DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
WO2017019897A1 (fr) | 2015-07-29 | 2017-02-02 | Novartis Ag | Polythérapies comprenant des molécules d'anticorps contre tim -3 |
EP4378957A2 (fr) | 2015-07-29 | 2024-06-05 | Novartis AG | Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1 |
KR20180041677A (ko) | 2015-08-28 | 2018-04-24 | 노파르티스 아게 | Mdm2 억제제 및 그의 조합물 |
CN105001151B (zh) * | 2015-08-28 | 2017-07-14 | 苏州明锐医药科技有限公司 | 布帕尼西中间体及其制备方法 |
EP3344624B8 (fr) | 2015-09-02 | 2023-11-29 | Takeda Pharmaceutical Company Limited | Inhibiteurs de tyk2 et leurs utilisations |
CN108137482B (zh) | 2015-09-08 | 2024-03-15 | 莫纳什大学 | 定向淋巴的前药 |
WO2017044720A1 (fr) | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Analogues de la rapamycine et leurs utilisations |
SI3364958T1 (sl) | 2015-10-23 | 2023-05-31 | Navitor Pharmaceuticals, Inc. | Modulatorji interakcije sestrina in gator2 ter njihova uporaba |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
US20180280370A1 (en) | 2015-11-02 | 2018-10-04 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
EP3370768B9 (fr) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
WO2017093905A1 (fr) | 2015-12-03 | 2017-06-08 | Novartis Ag | Traitement du cancer avec un inhibiteur de pi3k chez un patient présélectionné comme ayant une mutation de pik3ca dans l'adntc |
EP3389664A4 (fr) | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | Inhibiteurs de caféine de mthfd2 et leurs utilisations |
CN106883185B (zh) * | 2015-12-15 | 2021-07-09 | 重庆博腾制药科技股份有限公司 | 一种4-氯-2-三氟甲基嘧啶的制备方法 |
CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
US11014882B2 (en) * | 2016-03-09 | 2021-05-25 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
DK3426243T3 (da) | 2016-03-09 | 2021-07-19 | Raze Therapeutics Inc | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf |
WO2017177230A1 (fr) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Méthodes de traitement du cancer |
EP3231799A1 (fr) * | 2016-04-14 | 2017-10-18 | Universität Basel | Dérivés de 4-(azétidin-1-yl)pyrimidine ayant une activité anti-mitotique et antiproliférative |
JP2019515041A (ja) | 2016-05-06 | 2019-06-06 | メリンタ セラピューティクス、 インコーポレイテッドMelinta Therapeutics, Inc. | 抗菌剤ならびにそれを作製および使用する方法 |
JP6991158B2 (ja) * | 2016-05-18 | 2022-02-10 | ピクール セラピューティクス アーゲー | 神経障害の治療法 |
CN109414415B (zh) | 2016-05-18 | 2023-05-02 | 拓客股份有限公司 | 皮肤病变的治疗 |
US10544137B2 (en) | 2016-06-02 | 2020-01-28 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof |
JP2019524872A (ja) | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | 癌の治療に有用なイミダゾピリミジン化合物 |
CN109906224B (zh) | 2016-06-20 | 2022-02-25 | 诺华股份有限公司 | 三唑吡啶化合物及其应用 |
RU2754856C2 (ru) | 2016-06-20 | 2021-09-08 | Новартис Аг | Кристаллические формы соединения триазолопиримидина |
EP3471727B1 (fr) | 2016-06-21 | 2020-12-09 | X4 Pharmaceuticals, Inc. | Inhibiteurs de cxcr4 et leurs utilisations |
CN109641838A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
JP7084624B2 (ja) | 2016-06-21 | 2022-06-15 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
EP3507367A4 (fr) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations |
CN106905294A (zh) * | 2016-07-08 | 2017-06-30 | 苏州科睿思制药有限公司 | 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法 |
WO2018064076A1 (fr) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Molécules de récepteurs d'engloutissement chimériques |
RU2758669C2 (ru) | 2016-09-27 | 2021-11-01 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк |
AU2017342464B2 (en) | 2016-10-14 | 2021-09-16 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
EP3528816A4 (fr) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | Inhibiteurs de tyk2 et leurs utilisations |
EP3538091A4 (fr) | 2016-11-08 | 2020-06-10 | Navitor Pharmaceuticals, Inc. | Inhibiteurs de la phényl amino pipéridine mtorc et leurs utilisations |
WO2018092064A1 (fr) | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinaisons d'inhibiteurs de mdm2 et d'inhibiteurs de bcl-xl |
US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
WO2018106636A1 (fr) | 2016-12-05 | 2018-06-14 | Raze Therapeutics, Inc. | Inhibiteurs de shmt et leurs utilisations |
WO2018115203A1 (fr) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Dérivés peptidiques ayant de nouvelles structures de liaison |
EP3565638B8 (fr) | 2017-01-06 | 2024-04-10 | BicycleRD Limited | Conjugué bicyclique pour traiter le cancer |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
US11179413B2 (en) | 2017-03-06 | 2021-11-23 | Novartis Ag | Methods of treatment of cancer with reduced UBB expression |
TWI783978B (zh) | 2017-03-08 | 2022-11-21 | 美商林伯士拉克許米公司 | Tyk2抑制劑、其用途及生產方法 |
EP3375778A1 (fr) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Dérivés d'aryl-pipéridine |
EP3375784A1 (fr) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Dérivés d'aza-dihydro-acridone |
WO2018185618A1 (fr) | 2017-04-03 | 2018-10-11 | Novartis Ag | Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement |
US11339144B2 (en) | 2017-04-10 | 2022-05-24 | Navitor Pharmaceuticals, Inc. | Heteroaryl Rheb inhibitors and uses thereof |
TWI776886B (zh) | 2017-04-26 | 2022-09-11 | 美商奈維特製藥公司 | Sestrin-gator2交互作用之調節劑及其用途 |
EP3615550A1 (fr) | 2017-04-27 | 2020-03-04 | BicycleTx Limited | Ligands peptidiques bicycliques et leurs utilisations |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
CN117860758A (zh) | 2017-05-23 | 2024-04-12 | 梅制药公司 | 联合疗法 |
WO2018215937A1 (fr) | 2017-05-24 | 2018-11-29 | Novartis Ag | Protéines à greffe de cytokine-anticorps anti-interleukine-7 et procédés d'utilisation dans le traitement du cancer |
PE20200303A1 (es) | 2017-05-24 | 2020-02-06 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer |
EP3630162A1 (fr) | 2017-05-24 | 2020-04-08 | Novartis AG | Protéines greffées anticorps-cytokine et méthodes d'utilisation |
CA3066774A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Molecules d'anticorps se liant a cd73 et leurs utilisations |
WO2018237173A1 (fr) | 2017-06-22 | 2018-12-27 | Novartis Ag | Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes |
US10899798B2 (en) | 2017-06-26 | 2021-01-26 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
JP7216705B2 (ja) | 2017-07-28 | 2023-02-02 | ニンバス ラクシュミ, インコーポレイテッド | Tyk2阻害剤およびその使用方法 |
EP3668887A1 (fr) | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Conjugués ligands peptidiques bicycliques et leurs utilisations |
WO2019034868A1 (fr) | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | Conjugués peptide bicyclique-ligand ppr-a et leurs utilisations |
WO2019036489A1 (fr) | 2017-08-14 | 2019-02-21 | Mei Pharma, Inc. | Polythérapie |
JP7290627B2 (ja) * | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム | Atrキナーゼの複素環式阻害剤 |
US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
CA3077739A1 (fr) | 2017-08-29 | 2019-03-07 | Puretech Lyt, Inc. | Promedicaments lipidiques orientant vers le systeme lymphatique |
JP2020532982A (ja) | 2017-09-08 | 2020-11-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの診断及び治療方法 |
US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
IL295603B2 (en) | 2017-09-22 | 2024-03-01 | Kymera Therapeutics Inc | Protein compounds and their uses |
US11708423B2 (en) | 2017-09-26 | 2023-07-25 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules and methods of use |
CN109651341A (zh) * | 2017-10-11 | 2019-04-19 | 上海医药工业研究院 | 二吗啉氰基嘧(吡)啶类衍生物及作为抗肿瘤药物应用 |
EP3694511A1 (fr) | 2017-10-13 | 2020-08-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polythérapie du cancer du pancréas |
US12000833B2 (en) | 2017-11-23 | 2024-06-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Marker for predicting the sensitivity to PI3K inhibitors |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
WO2019126378A1 (fr) | 2017-12-19 | 2019-06-27 | Ariya Therapeutics, Inc. | Promédicaments lipidiques d'acide mycophénolique et leurs utilisations |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
JP2021506978A (ja) | 2017-12-22 | 2021-02-22 | ラヴェンナ ファーマシューティカルズ,インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体 |
US11919902B2 (en) | 2017-12-22 | 2024-03-05 | Hibercell, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
IL275649B2 (en) | 2017-12-26 | 2023-12-01 | Kymera Therapeutics Inc | IRAK joints and used in them |
EP3737675A4 (fr) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Ligands crbn et leurs utilisations |
WO2019140380A1 (fr) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Agents de dégradation de protéines et utilisations associées |
KR20200116481A (ko) | 2018-01-29 | 2020-10-12 | 메르크 파텐트 게엠베하 | Gcn2 억제제 및 이의 용도 |
CN111867581B (zh) | 2018-01-29 | 2023-12-26 | 默克专利股份有限公司 | Gcn2抑制剂及其用途 |
EA202091742A1 (ru) | 2018-02-27 | 2021-02-19 | Артакс Биофарма Инк. | ПРОИЗВОДНЫЕ ХРОМЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ВЗАИМОДЕЙСТВИЯ TCR-Nck |
JP7444781B2 (ja) | 2018-03-28 | 2024-03-06 | セロ・セラピューティクス・インコーポレイテッド | 細胞免疫療法組成物およびその使用 |
EP3774906A1 (fr) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Récepteurs tim4 chimériques et leurs utilisations |
EP3774869A1 (fr) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Vecteurs d'expression pour récepteurs d'envahissement chimériques, cellules hôtes génétiquement modifiées, et leurs utilisations |
MX2020010437A (es) | 2018-04-05 | 2021-01-29 | Sumitomo Pharma Oncology Inc | Inhibidores de axl cinasa y uso de los mismos. |
WO2019194220A1 (fr) * | 2018-04-06 | 2019-10-10 | 日本曹達株式会社 | Composé (hétéro)arylsulfonamide et agent de lutte contre les organismes nuisibles |
WO2019199864A1 (fr) * | 2018-04-10 | 2019-10-17 | Neuropore Therapies, Inc. | Dérivés d'aryle et d'hétéroaryle tri-substitués utilisés en tant que modulateurs de la pi3-kinase et des voies de l'autophagie |
ES2929292T3 (es) | 2018-04-10 | 2022-11-28 | Neuropore Therapies Inc | Derivados de morfolina como inhibidores de Vps34 |
JP7479293B2 (ja) | 2018-04-24 | 2024-05-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | プテリジノン化合物およびその使用 |
TWI813673B (zh) | 2018-04-24 | 2023-09-01 | 德商馬克專利公司 | 抗增生化合物及其用途 |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
WO2019232244A2 (fr) | 2018-05-31 | 2019-12-05 | Novartis Ag | Molécules d'anticorps anti-cd73 et leurs utilisations |
FI3813946T3 (fi) | 2018-06-15 | 2024-06-25 | Janssen Pharmaceutica Nv | Rapamysiinianalogeja ja niiden käyttötapoja |
CN108864067B (zh) * | 2018-06-20 | 2020-05-12 | 郑州大学 | 一种2-炔丙巯基-5-氰基嘧啶类衍生物及其制备方法和应用 |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
EP3817748A4 (fr) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | Ligands crbn tricycliques et leurs utilisations |
JP2021530554A (ja) | 2018-07-26 | 2021-11-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤 |
DK3837256T3 (da) | 2018-08-17 | 2023-05-30 | Novartis Ag | Ureaforbindelser og sammensætninger som smarca2/brm-atpase-hæmmere |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
JP2022500499A (ja) | 2018-09-07 | 2022-01-04 | ピク セラピューティクス, インコーポレイテッド | Eif4e阻害剤およびその使用 |
AU2019360941A1 (en) | 2018-10-15 | 2021-04-29 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
JP2022512779A (ja) | 2018-10-23 | 2022-02-07 | バイスクルテクス・リミテッド | 二環式ペプチドリガンドおよびその使用 |
CA3117336A1 (fr) | 2018-10-24 | 2020-04-30 | Navitor Pharmaceuticals, Inc. | Polymorphies d'acide (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoique pour la modulation de mtorc1 |
EP3873532A1 (fr) | 2018-10-31 | 2021-09-08 | Novartis AG | Conjugué médicament-anticorps anti-dc-sign |
CN113423427A (zh) | 2018-11-30 | 2021-09-21 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
EP3886843A4 (fr) | 2018-11-30 | 2022-08-31 | Nimbus Lakshmi, Inc. | Inhibiteurs de tyk2 et leurs utilisations |
EP3670659A1 (fr) | 2018-12-20 | 2020-06-24 | Abivax | Biomarqueurs et leurs utilisations dans le traitement d'infections virales, d'inflammations ou du cancer |
BR112021011894A2 (pt) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
JP2022515760A (ja) | 2018-12-21 | 2022-02-22 | ノバルティス アーゲー | Pmel17に対する抗体及びその結合体 |
CN109651297B (zh) * | 2019-01-22 | 2022-05-27 | 杭州壹瑞医药科技有限公司 | 一种n-苄基-n-芳基磺酰胺类衍生物及制备和应用 |
CN109705033B (zh) * | 2019-01-22 | 2021-03-30 | 杭州壹瑞医药科技有限公司 | N-杂芳基磺酰胺类衍生物及制备和应用 |
CN113348021A (zh) | 2019-01-23 | 2021-09-03 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
WO2020167990A1 (fr) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques |
WO2020165600A1 (fr) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Conjugués peptide-ligand bicyclique et leurs utilisations |
MX2021011289A (es) | 2019-03-22 | 2021-11-03 | Sumitomo Pharma Oncology Inc | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. |
SG11202110828UA (en) | 2019-04-02 | 2021-10-28 | Bicycletx Ltd | Bicycle toxin conjugates and uses thereof |
US11485750B1 (en) | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
WO2020243423A1 (fr) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Inhibiteurs de tead et leurs utilisations |
TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
WO2021001426A1 (fr) | 2019-07-02 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Utilisation d'une imagerie d'élasticité ultrarapide pour la détection de cancers du pancréas |
EP3993786A1 (fr) | 2019-07-02 | 2022-05-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de traitement prophylactique du cancer chez des patients souffrant de pancréatite |
WO2021001431A1 (fr) | 2019-07-02 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Utilisation d'inhibiteurs sélectifs de pi3ka pour traiter une maladie métastatique chez des patients souffrant de cancer du pancréas |
MX2022000164A (es) | 2019-07-03 | 2022-04-01 | Sumitomo Pharma Oncology Inc | Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos. |
TW202118770A (zh) | 2019-07-30 | 2021-05-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
AU2020345962A1 (en) | 2019-09-11 | 2022-03-31 | Vincere Biosciences, Inc. | USP30 inhibitors and uses thereof |
JP2022547719A (ja) | 2019-09-13 | 2022-11-15 | ニンバス サターン, インコーポレイテッド | Hpk1アンタゴニストおよびその使用 |
WO2021053559A1 (fr) | 2019-09-18 | 2021-03-25 | Novartis Ag | Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies |
CN114746414A (zh) | 2019-09-26 | 2022-07-12 | 诺华公司 | 氮杂-喹啉化合物及其用途 |
WO2021067875A1 (fr) | 2019-10-03 | 2021-04-08 | Cero Therapeutics, Inc. | Récepteurs tim4 chimériques et leurs utilisations |
EP4051259A4 (fr) | 2019-11-01 | 2023-11-22 | Navitor Pharmaceuticals, Inc. | Méthodes de traitement à l'aide d'un modulateur de mtorc1 |
US11819476B2 (en) | 2019-12-05 | 2023-11-21 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
WO2021127283A2 (fr) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
IL293917A (en) | 2019-12-17 | 2022-08-01 | Kymera Therapeutics Inc | Iraq joints and their uses |
CN115297931A (zh) | 2019-12-23 | 2022-11-04 | 凯麦拉医疗公司 | Smarca降解剂和其用途 |
WO2021159021A1 (fr) | 2020-02-05 | 2021-08-12 | Puretech Lyt, Inc. | Promédicaments lipidiques de neurostéroïdes |
WO2021159993A1 (fr) * | 2020-02-14 | 2021-08-19 | Pharmablock Sciences (Nanjing) , Inc. | Inhibiteurs de la kinase associée au récepteur de l'interleukine 1 (irak)/tyrosine kinase du récepteur de type fms (flt3), leurs produits pharmaceutiques et leurs procédés |
CA3170411A1 (fr) | 2020-03-03 | 2021-09-10 | Christopher L. Vandeusen | Inhibiteurs d'eif4e et leurs utilisations |
CA3171258A1 (fr) | 2020-03-19 | 2021-09-23 | Nan JI | Agents de degradation de mdm2 et leurs utilisations |
US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
KR20210158019A (ko) | 2020-06-23 | 2021-12-30 | 주식회사 온코빅스 | 포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물 |
AR123185A1 (es) | 2020-08-10 | 2022-11-09 | Novartis Ag | Compuestos y composiciones para inhibir ezh2 |
WO2022036265A1 (fr) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Récepteurs chimériques tim et leurs utilisations |
WO2022036285A1 (fr) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions et méthodes de traitement du cancer à l'aide de récepteurs tim chimériques en association avec des inhibiteurs de la poly(adp-ribose)polymérase |
WO2022036287A1 (fr) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Récepteurs chimériques anti-cd72 et utilisations de ceux-ci |
AU2021327130A1 (en) | 2020-08-17 | 2023-03-02 | Bicycletx Limited | Bicycle conjugates specific for Nectin-4 and uses thereof |
WO2022043558A1 (fr) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Méthode de traitement de cancers exprimant le psma |
EP4204021A1 (fr) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Méthode de traitement de cancers exprimant le psma |
WO2022043556A1 (fr) | 2020-08-31 | 2022-03-03 | Novartis Ag | Composition pharmaceutique stable |
TW202227089A (zh) | 2020-11-30 | 2022-07-16 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療pik3ca突變癌症的組合療法 |
KR20230131189A (ko) | 2020-12-02 | 2023-09-12 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
WO2022120353A1 (fr) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Inhibiteurs de tead et leurs utilisations |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
WO2022167457A1 (fr) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Antagonistes de gpr84 et leurs utilisations |
JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Gpr84アンタゴニストおよびその使用 |
IL304905A (en) | 2021-02-15 | 2023-10-01 | Kymera Therapeutics Inc | IRAK4 joints and their uses |
BR112023017213A2 (pt) | 2021-02-26 | 2023-11-21 | Kelonia Therapeutics Inc | Vetores lentivirais direcionados a linfócitos |
US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
KR20230158659A (ko) * | 2021-03-18 | 2023-11-21 | 쑤저우 궈쾅 팜테크 코포레이션 리미티드 | Ctla-4 소분자 분해제 및 그 응용 |
US20220363696A1 (en) | 2021-04-13 | 2022-11-17 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
KR20230170738A (ko) | 2021-04-16 | 2023-12-19 | 노파르티스 아게 | 항체 약물 접합체 및 이의 제조 방법 |
EP4323066A1 (fr) | 2021-04-16 | 2024-02-21 | Ikena Oncology, Inc. | Inhibiteurs de mek et leurs utilisations |
EP4376874A1 (fr) | 2021-07-28 | 2024-06-05 | Cero Therapeutics, Inc. | Récepteurs tim4 chimériques et leurs utilisations |
EP4392421A1 (fr) | 2021-08-25 | 2024-07-03 | PIC Therapeutics, Inc. | Inhibiteurs d'eif4e et leurs utilisations |
CN118103368A (zh) | 2021-08-25 | 2024-05-28 | 皮克医疗公司 | Eif4e抑制剂及其用途 |
CA3240381A1 (fr) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Pyrimidines et leurs procedes d'utilisation |
WO2023114984A1 (fr) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Inhibiteurs de tead et leurs utilisations |
CN114213340B (zh) | 2022-02-22 | 2022-06-07 | 北京蓝晶微生物科技有限公司 | 2,4-二氨基嘧啶氧化物的制备方法 |
CN114591326B (zh) * | 2022-02-28 | 2024-02-27 | 上海筛杰生物医药有限公司 | Cct-251921的中间体及其制备方法 |
WO2023173053A1 (fr) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Inhibiteurs de mek et leurs utilisations |
WO2023173057A1 (fr) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Inhibiteurs de mek et leurs utilisations |
WO2023211889A1 (fr) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Composés polymorphes et leurs utilisations |
US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
WO2024028363A1 (fr) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Hétéroaryl-carboxamide et antagonistes de gpr84 associés et leurs utilisations |
WO2024028365A1 (fr) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Antagonistes de gpr84 contenant de la pyridone substituée et leurs utilisations |
WO2024028364A1 (fr) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyle et antagonistes de gpr84 apparentés et leurs utilisations |
WO2024112894A1 (fr) | 2022-11-22 | 2024-05-30 | PIC Therapeutics, Inc. | Inhibiteurs d'eif4e et leurs utilisations |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB581334A (en) | 1943-09-29 | 1946-10-09 | Francis Henry Swinden Curd | New pyrimidine compounds |
AT340933B (de) * | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体 |
US4323581A (en) | 1978-07-31 | 1982-04-06 | Johnson & Johnson | Method of treating carcinogenesis |
US4329726A (en) * | 1978-12-01 | 1982-05-11 | Raychem Corporation | Circuit protection devices comprising PTC elements |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
EP0303697B1 (fr) | 1987-03-09 | 1997-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Derives de la substance physiologiquement active k-252 |
US4994386A (en) | 1987-07-13 | 1991-02-19 | Pharmacia Diagnostics, Inc. | Production of HBLV virus in the HSB-2 cell line |
US4904768A (en) | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
EP0383919A4 (en) | 1988-02-04 | 1992-08-05 | Kyowa Hakko Kogyo Co., Ltd. | Staurosporin derivatives |
US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
US5451700A (en) | 1991-06-11 | 1995-09-19 | Ciba-Geigy Corporation | Amidino compounds, their manufacture and methods of treatment |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
EP0540185A1 (fr) | 1991-10-10 | 1993-05-05 | Schering Corporation | Dérivés de staurosporine-N-oxide N-substitués |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
AU3064992A (en) | 1991-11-08 | 1993-06-07 | University Of Southern California | Compositions containing k-252 compounds for potentiation of neurotrophin activity |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
US5948898A (en) | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
US5756494A (en) | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
US5621100A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
JP3608788B2 (ja) | 1992-08-31 | 2005-01-12 | ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ | Mage−3遺伝子から誘導されてhla−a1により提示される単離されたノナペプチドおよびそれらの用途 |
DE69331228T4 (de) | 1992-09-21 | 2002-09-05 | Kyowa Hakko Kogyo Kk | Heilmittel für thrombozytopenia |
EP1238986B1 (fr) | 1992-10-28 | 2008-06-25 | Genentech, Inc. | Utilisation d'antagonistes du facteur de croissance cellulaire VEGF |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
KR100341341B1 (ko) | 1993-07-15 | 2002-11-25 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | 이미다조[4,5-c]피리딘-4-아민 |
US5478932A (en) | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
ATE456367T1 (de) | 1993-12-23 | 2010-02-15 | Lilly Co Eli | Proteinkinase c inhibitoren |
US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
ATE205483T1 (de) | 1995-03-30 | 2001-09-15 | Pfizer | Chinazolinderivate |
EP0767170B1 (fr) | 1995-04-13 | 2002-10-23 | Taiho Pharmaceutical Co., Ltd. | Nouveaux derives 4,6-diarylpyrimidine et leurs sels |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
WO1997007081A2 (fr) | 1995-08-11 | 1997-02-27 | Yale University | Synthese d'indolocarbazols glycosyles |
FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
WO1997021701A1 (fr) | 1995-12-08 | 1997-06-19 | Janssen Pharmaceutica N.V. | Derives de la (imidazol-5-yl)methyl-2-quinoleinone comme inhibiteur de la proteine farnesyle-transferase |
KR100447918B1 (ko) | 1996-07-25 | 2005-09-28 | 동아제약주식회사 | 대장을포함한위장관보호작용을갖는플라본및플라바논화합물 |
IL128124A0 (en) | 1996-08-02 | 1999-11-30 | Genesense Technologies Inc | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase |
JP3734907B2 (ja) * | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
DE69832715T2 (de) | 1997-07-12 | 2007-01-11 | Cancer Research Technology Ltd. | Cyclin-abhängige-kinase inhibierende purinderivate |
AU727013B2 (en) * | 1997-07-24 | 2000-11-30 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent comprising the same as effective component |
US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
US6150362A (en) * | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
ATE236136T1 (de) * | 1998-01-16 | 2003-04-15 | Hoffmann La Roche | Benzosulfonderivate |
NZ508815A (en) | 1998-05-29 | 2005-02-25 | Sugen Inc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
JP4533534B2 (ja) | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | グリコーゲンシンターゼキナーゼ3のインヒビター |
US20030083242A1 (en) | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
CA2359680A1 (fr) | 1999-01-22 | 2000-07-27 | David M. Armistead | Inhibiteurs de kinase |
US6495558B1 (en) * | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
ATE299865T1 (de) | 1999-05-04 | 2005-08-15 | Schering Corp | Piperazinderivate verwendbar als ccr5 antagonisten |
CN1524527A (zh) | 1999-05-04 | 2004-09-01 | ���鹫˾ | 用作ccr5拮抗剂的哌啶衍生物 |
CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
CA2376951A1 (fr) | 1999-06-30 | 2001-01-04 | Peter J. Sinclair | Composes inhibiteurs de la kinase src |
WO2001000207A1 (fr) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Composes inhibiteurs de la src kinase |
EP1206265B1 (fr) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Composes inhibiteurs de la src kinase |
CA2379035A1 (fr) | 1999-07-13 | 2001-01-18 | Shiro Akinaga | Derives de staurosporine |
ATE250053T1 (de) | 1999-07-15 | 2003-10-15 | Pharmacopeia Inc | Bradikinin b1 rezeptor antagonisten |
PT1676845E (pt) | 1999-11-05 | 2008-08-05 | Astrazeneca Ab | Novos derivados de quinazolina |
AU3977001A (en) | 2000-02-15 | 2001-08-27 | Sugen Inc | Pyrrole substituted 2-indolinone protein kinase inhibitors |
IL151946A0 (en) | 2000-03-29 | 2003-04-10 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
JP2003531148A (ja) | 2000-04-12 | 2003-10-21 | ジェネーラ・コーポレーション | 保護されていない7−α−ヒドロキシ基を有する中間体を使用する、7−α−ヒドロキシ3−アミノ置換ステロイドの調製のためのプロセス |
CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
KR100711042B1 (ko) | 2000-04-28 | 2007-04-24 | 다나베 세이야꾸 가부시키가이샤 | 환상 화합물 |
EP1296977A1 (fr) * | 2000-06-23 | 2003-04-02 | Bristol-Myers Squibb Pharma Company | Inhibiteurs du facteur xa a substitution heteroaryl-phenyle |
CN1211382C (zh) | 2000-06-30 | 2005-07-20 | 葛兰素集团有限公司 | 喹唑啉二甲苯磺酸盐化合物 |
EP1317433A2 (fr) | 2000-09-06 | 2003-06-11 | Chiron Corporation | Inhibiteurs de glycogene-synthase kinase 3 |
BRPI0113757B1 (pt) | 2000-09-11 | 2017-05-23 | Chiron Corp | derivados de quinolinona como inibibores de tirosina quinase |
AU2001291013A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6677450B2 (en) | 2000-10-06 | 2004-01-13 | Bristol-Myers Squibb Company | Topoisomerase inhibitors |
SE0004053D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
HUP0400908A3 (en) | 2000-12-21 | 2010-03-29 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them |
US6919183B2 (en) | 2001-01-16 | 2005-07-19 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
WO2002062766A2 (fr) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Composes de liaison au recepteur de la melanocortine-4 et procedes d'utilisation de tels composes |
WO2002062826A1 (fr) | 2001-02-07 | 2002-08-15 | Vadim Viktorovich Novikov | Procede de fabrication des peptides |
WO2002096876A1 (fr) * | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Composes de carbamate et d'oxamide inhibant la production de cytokine |
EP1397142A4 (fr) | 2001-06-19 | 2004-11-03 | Bristol Myers Squibb Co | Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7 |
US20040186172A1 (en) | 2001-07-02 | 2004-09-23 | Houssam Ibrahim | Oxaliplatin active substance with a very low content of oxalic acid |
US6603000B2 (en) * | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
KR100484504B1 (ko) | 2001-09-18 | 2005-04-20 | 학교법인 포항공과대학교 | 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물 |
WO2003030909A1 (fr) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer |
US20030134846A1 (en) | 2001-10-09 | 2003-07-17 | Schering Corporation | Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors |
WO2003077902A1 (fr) | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Procede de synthese de promedicaments a partir de derives de 1-acyl-alkyl et compositions correspondantes |
EP1485380B1 (fr) * | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines inhibitrices des proteines kinases |
US7179826B2 (en) * | 2002-03-15 | 2007-02-20 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
ATE466580T1 (de) * | 2002-03-15 | 2010-05-15 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
DE60314603T2 (de) * | 2002-03-15 | 2008-02-28 | Vertex Pharmaceuticals Inc., Cambridge | Zusammensetzungen brauchbar als protein-kinase-inhibitoren |
MXPA04009541A (es) | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
US6900342B2 (en) | 2002-05-10 | 2005-05-31 | Dabur India Limited | Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof |
US6727272B1 (en) | 2002-07-15 | 2004-04-27 | Unitech Pharmaceuticals, Inc. | Leflunomide analogs for treating rheumatoid arthritis |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
JP2006515274A (ja) | 2002-10-08 | 2006-05-25 | マサチューセッツ・インスティテュート・オブ・テクノロジー | コレステロール輸送の調節のための化合物 |
CA2507100C (fr) * | 2002-11-21 | 2012-10-09 | Chiron Corporation | Pyrimidines 2,4,6-trisubstitutees utilisees comme inhibiteurs de phosphotidylinositol (pi) 3-kinase et leur utilisation dans le traitement du cancer |
EP1587473A4 (fr) | 2002-12-27 | 2008-08-13 | Novartis Vaccines & Diagnostic | Thiosemicarbazones antiviraux et immunostimulants |
US8193185B2 (en) | 2003-01-21 | 2012-06-05 | Novartis Vaccines And Diagnostics, Inc. | Use of tryptanthrin compounds for immune potentiation |
CA2519677A1 (fr) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Heterocycles a 6 elements a substitution biaryle en tant que bloqueurs des canaux sodiques |
CA2520124A1 (fr) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Utilisation de composes de benzazole pour l' immunostimulation |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
US20060229308A1 (en) | 2003-07-15 | 2006-10-12 | Neurogen Corporation | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands |
JP2007534624A (ja) | 2003-07-16 | 2007-11-29 | ニューロジェン・コーポレーション | ビアリールピペラジニル−ピリジン類縁体 |
PE20050952A1 (es) * | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415365D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
JP2009523161A (ja) | 2006-01-11 | 2009-06-18 | アストラゼネカ アクチボラグ | モルホリノピリミジン誘導体と療法におけるその使用 |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
WO2008098058A1 (fr) * | 2007-02-06 | 2008-08-14 | Novartis Ag | Inhibiteurs de la pi3-kinase et procédés de leur utilisation |
EP2673268A1 (fr) | 2011-02-11 | 2013-12-18 | Dana-Farber Cancer Institute, Inc. | Procédé d'inhibition de cellules tumorales d'hamartome |
-
2007
- 2007-01-18 JO JO200713A patent/JO2660B1/en active
- 2007-01-19 PE PE2007000060A patent/PE20071322A1/es active IP Right Grant
- 2007-01-19 AR ARP070100237A patent/AR059087A1/es not_active Application Discontinuation
- 2007-01-19 TW TW096102123A patent/TWI385170B/zh active
- 2007-01-19 TW TW101150766A patent/TW201315723A/zh unknown
- 2007-01-22 NZ NZ569771A patent/NZ569771A/en unknown
- 2007-01-22 ES ES10173136T patent/ES2427624T3/es active Active
- 2007-01-22 RS RS20130353A patent/RS52928B/en unknown
- 2007-01-22 DK DK10173136.2T patent/DK2261223T3/da active
- 2007-01-22 PL PL07716906T patent/PL1984350T3/pl unknown
- 2007-01-22 AT AT07716906T patent/ATE478064T1/de active
- 2007-01-22 DE DE602007008529T patent/DE602007008529D1/de active Active
- 2007-01-22 KR KR1020087020198A patent/KR101353829B1/ko active IP Right Grant
- 2007-01-22 SI SI200731300T patent/SI2261223T1/sl unknown
- 2007-01-22 PL PL10173136T patent/PL2261223T3/pl unknown
- 2007-01-22 AU AU2007206048A patent/AU2007206048B2/en active Active
- 2007-01-22 GE GEAP200710824A patent/GEP20115147B/en unknown
- 2007-01-22 PT PT07716906T patent/PT1984350E/pt unknown
- 2007-01-22 EP EP10173136.2A patent/EP2261223B1/fr active Active
- 2007-01-22 SM SM200800048T patent/SMP200800048B/it unknown
- 2007-01-22 ME MEP-39/08A patent/MEP3908A/xx unknown
- 2007-01-22 RS RSP-2010/0439A patent/RS51548B/en unknown
- 2007-01-22 EP EP07716906A patent/EP1984350B1/fr active Active
- 2007-01-22 DK DK07716906.8T patent/DK1984350T3/da active
- 2007-01-22 SI SI200730406T patent/SI1984350T1/sl unknown
- 2007-01-22 MY MYPI20082622A patent/MY144233A/en unknown
- 2007-01-22 EA EA200801680A patent/EA018083B1/ru not_active IP Right Cessation
- 2007-01-22 CA CA2636993A patent/CA2636993C/fr active Active
- 2007-01-22 PT PT101731362T patent/PT2261223E/pt unknown
- 2007-01-22 ES ES07716906T patent/ES2351172T3/es active Active
- 2007-01-22 JP JP2008551469A patent/JP5161110B2/ja active Active
- 2007-01-22 UA UAA200809431A patent/UA96284C2/ru unknown
- 2007-01-22 BR BRPI0707189-2A patent/BRPI0707189B1/pt active IP Right Grant
- 2007-01-22 ME MEP-2008-39A patent/ME00012B/fr unknown
- 2007-01-22 CN CN2007800063742A patent/CN101389622B/zh active Active
- 2007-01-22 US US12/161,537 patent/US8217035B2/en active Active
- 2007-01-22 WO PCT/US2007/001708 patent/WO2007084786A1/fr active Application Filing
-
2008
- 2008-07-09 ZA ZA2008/06017A patent/ZA200806017B/en unknown
- 2008-07-10 IL IL192763A patent/IL192763A/en active IP Right Grant
- 2008-07-18 GT GT200800143A patent/GT200800143A/es unknown
- 2008-07-18 CR CR10163A patent/CR10163A/es unknown
- 2008-07-18 TN TNP2008000305A patent/TNSN08305A1/en unknown
- 2008-07-18 EC EC2008008630A patent/ECSP088630A/es unknown
- 2008-07-21 SV SV2008002984A patent/SV2008002984A/es unknown
- 2008-07-21 HN HN2008001144A patent/HN2008001144A/es unknown
- 2008-08-01 NO NO20083389A patent/NO342183B1/no unknown
- 2008-08-06 MA MA31157A patent/MA30208B1/fr unknown
-
2009
- 2009-03-17 HK HK09102514.4A patent/HK1122031A1/xx unknown
-
2010
- 2010-11-09 HR HR20100603T patent/HRP20100603T1/hr unknown
- 2010-11-12 CY CY20101101021T patent/CY1111091T1/el unknown
-
2012
- 2012-05-14 US US13/471,111 patent/US8563549B2/en active Active
-
2013
- 2013-08-22 HR HRP20130796TT patent/HRP20130796T1/hr unknown
-
2018
- 2018-06-01 AR ARP180101483A patent/AR112118A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100603T1 (hr) | Derivati pirimidina koji se koriste kao inhibitori pi-3 kinaze | |
RU2277911C2 (ru) | Модуляторы аденозиновых рецепторов | |
HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
RU2009125897A (ru) | Ингибиторы фосфоинозитид-3-киназы и способы их применения | |
AU2009227013B2 (en) | Novel heterocyclic compounds and uses therof | |
AU2015353210B2 (en) | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | |
KR101985984B1 (ko) | 키나아제 저해제로서의 벤조니트릴 유도체 | |
RU2009125916A (ru) | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения | |
RU2417994C2 (ru) | Производные пиразина, полезные в качестве антагонистов аденозинового рецептора | |
JP2010512337A5 (fr) | ||
HRP20160118T1 (hr) | HETEROCIKLIÄŚKI DERIVAT KAO INHIBITOR MIKROSOMSKIH SINTAZA PROSTAGLANDINA E (mPGEs) | |
JP2011510995A5 (fr) | ||
CA2997039C (fr) | Compose pyrimidine a substitution 2,4-di-(groupe azote), son procede de preparation et son utilisation | |
US20080182870A1 (en) | PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | |
HRP20160635T1 (hr) | Inhibitori pirimidina pde10 | |
CN109328187A (zh) | 一种具有fgfr抑制活性的新型化合物及其制备和应用 | |
CA3042960A1 (fr) | Inhibiteur de fgfr4, son procede de preparation et son utilisation pharmaceutique | |
HRP20201400T1 (hr) | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
PE20090835A1 (es) | Derivados de quinazolina como inhibidores de la pi3 quinasa | |
JP2010512338A5 (fr) | ||
RU2014149684A (ru) | Производные аминохиназолина и пиридопиримидина | |
JP2019505595A5 (fr) | ||
CA2528848A1 (fr) | Utilisation de derives de la thienopyrimidine comme inhibiteurs des canaux potassiques | |
JP2016514717A5 (fr) | ||
RU2019109039A (ru) | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств |